Search results
Results from the WOW.Com Content Network
The company was listed on the Toronto Stock Exchange and the New York Stock Exchange. [1] YM BioSciences was the first company from any major-market country to enter into a relationship with the Cuban Government for the development of a number of that country's biopharmaceuticals, with first licenses concluding in 1995.
Giddy from GileadIf you owned shares in YM Biosciences (ASE: YMI) , you're. Santa came early for some investors. Several health-care stocks took a sleigh ride up the charts. Here are three of the ...
Gilead Sciences Completes Acquisition of YM BioSciences FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NAS: GILD) today announced that it has completed its acquisition of YM ...
For premium support please call: 800-290-4726 more ways to reach us
He was a founding director of YM BioSciences, which was sold to Gilead Sciences in 2013 for $540 million. [8] YM BioSciences commercialized bioscience technology in Cuba and made significant research breakthroughs in Myelofibrosis, a rare bone marrow cancer (See Momelotinib and Nimotuzumab). While in Cuba, Williams was recommended to seek the ...
Nimotuzumab (h-R3, [2] BIOMAb EGFR, Biocon, India; [3] TheraCIM, CIMYM Biosciences, Canada; Theraloc, Oncoscience, Europe, CIMAher, Center of Molecular Immunology, Havana, Cuba) is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was ...
For premium support please call: 800-290-4726 more ways to reach us
Need help? Call us! 800-290-4726 Login / Join. Mail